AstraZeneca Stock (AZN) Hits 1-Year High on Strong Earnings
AstraZeneca shares surged to a one-year peak, buoyed by better-than-expected Q3 earnings and raised full-year guidance. The pharmaceutical giant's Nasdaq-listed stock climbed to $87.69, pushing its market capitalization to $263 billion.
In London trading, the company simultaneously set new records, cementing its position as the LSE's most valuable listing. Revenue growth of 12% to $15.19 billion and a 14% EPS increase to $1.19 outpaced analyst projections.